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Introduction
In the daily practice of anaesthesia, patients who are 
infected with the human immunodeficiency virus (HIV) will 
present. These patients can be at various stages of the 
disease process, and may or may not be on antiretroviral 
therapy (ART). This article will concentrate mainly on the 
clinical and practical aspects of dealing with a patient 
with HIV for anaesthetists. 
Clinical manifestations
Patients who are infected with HIV may present at 
any stage of the disease process, and each stage is 
characterised by the presence of certain clinical stigmata. 
The World Health Organization (WHO) has developed a 
clinical staging system ranging from Stage 1 (essentially 
asymptomatic) to Stage 4 [acquired immune deficiency 
syndrome (AIDS)-defining].
By taking a history, examining the patient, and carrying 
out special investigations, the stage of the disease process 
in the patient can be determined. 
The following symptoms and signs should be sought during 
the taking of the history and the examination:
Clinical Stage 1
• Asymptomatic
• Persistent generalised lymphadenopathy
• Performance status 1: asymptomatic with normal 
activity.
Clinical Stage 2
• Unexplained persistent hepatosplenomegaly
• Papular pruritic eruptions
• Extensive wart virus infection
• Extensive molluscum contagiosum
• Fungal nail infections
• Recurrent oral ulcerations
• Unexplained persistent parotid enlargement
• Lineal gingival erythema
• Herpes zoster
• Recurrent or chronic upper respiratory tract infections, 
such as otitis media, otorrhoea, sinusitis, or tonsillitis
• Performance status 2: symptomatic, but nearly fully 
active.
Clinical Stage 3
• Unexplained moderate malnutrition, that does not 
adequately respond to standard therapy
• Unexplained persistent diarrhoea (14 days or more)
• Unexplained persistent fever (above 37.5oC intermit-
tent, or constant for longer than one month)
• Persistent oral candidiasis (after the first six to eight 
weeks of life)
• Oral hairy leukoplakia
• Acute necrotising ulcerative gingivitis or periodontitis
• Lymph node tuberculosis
• Pulmonary tuberculosis
• Severe recurrent bacterial pneumonia
• Symptomatic lymphoid interstitial pneumonitis
• Chronic HIV-associated lung disease, including 
bronchiectasis
• Unexplained anaemia (< 8 g/dl), neutropenia (< 0.5 x 
109 per litre) and/or chronic thrombocytopenia (< 50 x 
109 per litre)
• Performance status 3: in bed < 50% of daytime of past 
month.
Clinical Stage 4
• Unexplained severe wasting, stunting, or severe 
malnutrition that does not respond to standard therapy
• Pneumocystis pneumonia
• Recurrent severe bacterial infections, such as empy-
ema, pyomyositis, bone or joint infection, or meningitis, 
but excluding pneumonia
• Chronic herpes simplex infection (oro-labial or cutane-
ous of more than one month’s duration, or visceral at 
any site)
• Extra pulmonary tuberculosis
• Kaposi’s sarcoma
• Oesophageal candidiasis, or candidiasis of the 
trachea, bronchi or lungs
• Central nervous system toxoplasmosis 
• HIV encephalopathy
• Cytomegalovirus infection: retinitis or cytomegalovirus 
infection that affects another organ
• Extra pulmonary cryptococcosis, including meningitis
• Disseminated endemic mycosis (extra pulmonary 
histoplasmosis and coccidiomycosis)
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• Chronic cryptosporidiosis
• Chronic isosporiasis
• Disseminated non-tuberculous mycobacterial infec- 
tion
• Cerebral or B-cell non-Hodgkin lymphoma
• Progressive multifocal leukoencephalopathy
• Symptomatic HIV-associated nephropathy, or HIV-
associated cardiomyopathy
• HIV-associated rectovaginal fistula
• Performance status 4: in bed > 50% of daytime of the 
past month
Special investigations
The choice of special investigations should be guided by 
the history and examination.
Blood tests
Blood tests should include: 
• A full blood count: anaemia, thrombocytopaenia, 
increased or decreased white cell count
• Urea and electrolyte: a low total CO2 may indicate the 
presence of a lactic acidosis, in which case, carrying 
out an arterial blood gas should be considered
• Clotting profile: hypercoagulability
• Liver function tests: hypoalbuminaemia, and raised 
liver enzymes, especially with nevirapine
• Arterial blood gas analysis: hyperlactataemia and 
lactic acidosis
• Viral load and CD4+ count: mortality is inversely related 
to CD4+ count
Chest X-ray
• Cardiac shadow abnormalities (pericardial effusion), 
and dilated cardiomyopathy
• Evidence of infection, such as bacterial pneumonia, 
Pneumocystis jiroveci pneumonia (PCP), tuberculosis
• Kaposi’s sarcoma of airway or mediastinum
• Mediastinal compression or lymphadenopathy.
Electrocardiogram
• Conduction defects
• Prolonged QT time
Antiretroviral drugs
Patients who are HIV positive may be on ART. These drugs 
can have significant side-effects, and can also interact 
with anaesthetic agents.
Treatment of patients (who are HIV positive) with 
antiretroviral drugs, is based on guidelines provided by the 
National Department of Health. 
Antiretroviral drugs (Table I) are classified as follows:
• Reverse transcriptase inhibitors which include 
nucleoside reverse transcriptase inhibitors (NRTIs), 
nucleotide reverse transcriptase inhibitors (NtRTIs), and 
non-nucleoside reverse transcriptase inhibitors (NNRTIs)
• Protease inhibitors (PIs)
• Entry inhibitors, including fusion inhibitors and 
chemokine co-receptor antagonists (CCRAs)
• Integrase inhibitors.
Who is eligible to receive antiretroviral 
treatment?
The Standardized National Eligibility Criteria for starting ART 
regimens in adults and adolescents are as follows:
• CD4 count < 200 cells/mm3 irrespective of clinical 
stage; or
• CD4 count < 350 cells/mm3 in patients with tuberculosis/
HIV, or in pregnant women; or  
• WHO Stage 4, irrespective of CD4 count; or
• Multi-drug-resistant (MDR)/extreme drug-resistant (XDR) 
tuberculosis, irrespective of CD4 count.
What are the antiretroviral treatment regimen in 
South Africa?
Table II lists the first-line antiretroviral treatment regimen in 
South Africa.
Table III lists the salvage therapy treatment regimen in 
South Africa.
Antiretroviral treatment drug side-effects
Reverse transcriptase inhibitors: NRTIs and NtRTIs 
• NRTIs are associated with many adverse effects, most 
of which are benign and self-limiting.
• Mainly renal elimination.
• Mitochondrial toxicity may result in pancreatitis, 
hepatosteatosis, peripheral neuropathy, and lactic 
acidosis.
• Abnormal fat deposition can result in central obesity 
and facial fat wasting, as well as deranged lipid 
distribution, leading to metabolic derangement.
• Zidovudine is associated with a high incidence of 
Table I: Examples of antiretroviral drugs














NRTIs = nucleoside reverse transcriptase inhibitors, NtRTIs = nucleotide reverse transcriptase inhibitors, NNRTIs = non-nucleoside reverse transcriptase inhibitors, CCRAs = chemokine 
co-receptor antagonists
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fatigue, headaches, and gastrointestinal side-effects. 
including severe nausea, vomiting and diarrhoea.
NNRTIs
• Rashes, including Steven-Johnson syndrome, and toxic 
epidermal necrolysis.
• Nevirapine is used in the prevention of mother-to-child 
transmission. It is also a potent inducer of cytochrome 
p450 enzymes. As a result, it induces its own 
metabolism, and may lead to a reduction in the effect 
of midazolam, rifampicin and oral contraceptives.
• Markedly increase opioid metabolism requires an 
increased dose of synthetic opioids.
• Premature atherosclerosis, metabolic syndrome 
with glucose intolerance, decreased high-density 
lipoprotein levels and hypercholesterolaemia also 
occur.
• NNRTIs have a very long half-life, resulting in a 
“hangover effect” on discontinuation, i.e. increased 
risk of resistance to ARV.
PIs
• All are associated with metabolic abnormalities, 
including dyslipidaemia, insulin resistance with 
hyperglycaemia, and lipodystrophy (“protease 
paunch”).
• Cause gastrointestinal tract disturbances and 
abnormal liver functions.
• Impair Vitamin D metabolism, leading to osteoporosis.
• The effects of midazolam and diazepam are 
potentiated, and require dose reduction. Lorazepam 
is probably safer.
• Significant reduction in metabolism of alfentanil 
and fentanyl is described. Reduction in clearance 
of fentanyl by nearly 70% has been described 
with ritonavir. Remifentanyl and morphine are safe 
alternatives. Pethidine is not recommended because 
of the risk of metabolite accumulation and seizures.
• Sodium thiopentone and dexamethasone may 
reduce PI concentration.
• Simvastatin and lovastatin are absolutely 
contraindicated, as there is a high risk of rhabdomyolysis 
and myopathies. Pravastatin is safe.
• PIs increase the cardiac toxicity of amiodarone, 
quinidine and disopyramide. May potentiate digoxin 
toxicity.
• Disulfiram-like reaction with metronidazole.
Fusion inhibitors
• Expensive
• Risk of hypersensitivity
• Neutropaenia.
CCRAs
• Elevations in liver function tests, coughing, diarrhoea 
and nausea.
Table II: First-line treatment
Patient group Treatment Comments





Efavirenez is preferred for tuberculosis co-infection.
Navirapine is preferred in pregnant women, or women of child-
bearing age who are not on reliable contraception.
Currently on stavudine-based




The patient should remain on stavudine if it is well tolerated. Early 
switch with any toxicity. Substitute tenofovir if the patient is at high 







Table III: Second-line treatment for patients who fail first-line treatment virologically
Patient group Treatment Comments






Virological failure must be followed by intensive adherence 
management as resuppression is often possible. If repeat viral load 
remains >1 000 in 3 months despite adherence intervention, switch.





Virological failure must be followed by intensive adherence 
management as resuppression is often possible. If repeat viral load 
remains > 1 000 in 3 months despite adherence intervention, switch.
Table III: Salvage therapy
Patient group Treatment Comments
Failing any second-line regimen Specialist referral Virological failure on protease inhibitors is almost always due to 
non-adherence. Intensively exploring and addressing issues relating 
to causes of non-adherence will most often lead to resuppression. If 
viral load remains high, refer where possible, but
maintain on failing regimen.
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Integrase inhibitors
• Elevations in amylase and liver function tests, pruritus 
and rashes, headaches.
Lactic acidosis
Lactic acidaemia can occur in patients taking NRTIs. 
The lactate is elevated in the presence of a normal pH, 
and is not of clinical importance, provided the patient is 
asymptomatic.
However, lactic acidosis is a rare, but potentially fatal 
complication of ART. It carries a mortality of up to 77%. 
The symptoms may be vague and non-specific, such as 
nausea, vomiting, abdominal pain, fatigue and weight 
loss. The patient may also present with hepatic steatosis 
and dysfunction. Treatment involves stopping the NRTI, 
and instituting supportive care. Patients booked for 
elective surgical procedures who have lactic acidosis 
should be postponed until the lactic acidosis has resolved.
Immune reconstitution inflammatory syndrome 
Immune reconstitution inflammatory syndrome (IRIS) occurs 
when improving immune function unmasks a previously 
occult opportunistic infection which subsequently presents 
with an unusually aggressive inflammatory presentation. 
Patients with advanced HIV may become ill with IRIS. 
usually during the first three months of ART. Tuberculosis is 
the most common presenting IRIS reaction in South Africa. 
About a third of patients starting ART when on treatment 
for tuberculosis, will experience recurrence of their 
tuberculosis signs and symptoms, or new manifestations. 
Rashes, including zoster, herpes, molluscum and others, 
cryptococcal meningitis, and hepatitis due to hepatitis B 
or C, are other manifestations of IRIS.
IRIS is not indicative of drug failure or side-effects, and is 
not a reason to stop ART.
Perioperative fasting
Patients should continue treatment protocol despite nil per 
os orders, as there is clear evidence of increased mortality 
and adverse events during temporary interruption of the 
ART regimen. ARVs may also be administered via gastric 
or jejunal feeding tubes.
Premedication
Beware of potential drug interactions with midazolam and 
diazepam. Lorazepam and oxazepam are safer.
Universal precautions
Universal precautions are essential, including gloving 
and eye-splash protection. Avoid unnecessary invasive 
procedures, and dispose of sharps safely. 
Potentially infectious materials include blood and blood-
stained fluids or materials, vaginal or penile secretions, 
and tissue fluids, including ascites, liquor, cerebrospinal 
fluid, pleural and pericardial fluid, and breast milk.
Sweat, tears, saliva, sputum, urine and stools, are generally 
considered to be non-infectious, unless contaminated by 
the above.
The risk of HIV infection from needle-stick injury is 0.3%, 
and the risk of HIV transmission from exposure to mucous 
membranes is 0.1%, and to non-intact skin, < 0.1%.
The highest risk of infection is injury from hollow-bore 
needles containing visible blood, large-volume exposure, 
a deep injury, and if the patient has a high viral load.
Intraoperative management
General anaesthesia
General anaesthesia results in immunosuppression within 
15 minutes of induction, and lasts for up to 11 days 
postoperatively. The possibility of unpredictable drug 
interactions must always be considered.
Etomidate is possibly the safest for induction (no 
metabolism by cytochrome P450). However, the risk of 
adrenal insufficiency should be considered. There are no 
clear contraindications to propofol or sodium thiopentone.
Desflurane is theoretically advantageous due to minimal 
metabolism.
Remifentanil is the opioid of choice. Morphine is generally 
safe. Doses must be tailored according to response, 
and may need to be increased in patients on NNRTIs, or 
reduced in patients using PIs. In general, pethidine should 
be avoided.
Scoline is probably safe. However, the risk of hyperkalaemia 
in patients with myopathy and neuropathy can exist.
Atracurium and cis-atracurium with organ-independent 
metabolism are theoretically safest.
Neuraxial and regional anaesthesia
This is the technique of choice in patients who are HIV 
positive, unless there is evidence of coagulopathy, sepsis, 
neuropathy or uraemia. 
A platelet count is recommended to exclude 
thrombocytopaenia, and exclude or document pre-
existing neuropathy. 
An epidural blood patch is not contraindicated, although 
conservative treatment is usually preferable.
Postoperatively
It is essential to resume ART without interruption.
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